Former Justice Department Prosecutor on Microdosing at Work

The future of business might be hallucinogenic!

So declares Rob Chesnut, the former general counsel, and Justice Department prosecutor, as he details the rise of microdosing in the corporate world. His recent article, "With More Microdosing at Work, It’s Time to Amend Usage Policies," stirs up thought-provoking debates around the increasing use of psychedelics in the workplace. Leaders like Elon Musk and Sergey Brin openly admit to using these substances, drawing attention to their potential benefits, such as enhanced performance and creativity and possibly better mental health solutions. While these substances are still mostly illegal, there's an urgent need to reassess our understanding and policies surrounding their use.

A Brave New World: From Taboo to Treatment

There's a growing acceptance of formerly taboo substances like psychedelics thanks to research uncovering their profound potential benefits. Traditional substances like psilocybin, LSD, and MDMA are under investigation for their therapeutic uses, specifically for treatment-resistant depression and PTSD. Not only are we learning more about the science behind these psychedelics, but we're also gaining insights into the history of psychedelics and their cultural significance.

Elon Musk's recent statements about ketamine as a better alternative to conventional antidepressants underscores this shift towards embracing psychedelic medicine. This attitude is reflected in the growing popularity of online platforms like Psychedelic Medicine Coalition, advocating for research and policy reform around these substances.

Former Justice Department Prosecutor on Microdosing at Work

Psychedelics and The Workplace: A Mind-Altering Perspective

The traditional 9-to-5 office setup is increasingly becoming a thing of the past, with remote work and flexible hours becoming the norm. This shift has brought with it an unexpected trend – the use of psychedelics to enhance creativity, focus, and productivity. The question then arises – is a microdosing employee "impaired," or are they actually at an advantage?

Those who microdose have reported enhanced creativity, problem-solving skills, and focus, all of which are vital in today's fast-paced and highly competitive corporate world. Some even consider it a form of nootropic, a brain-enhancing supplement that boosts cognitive function. With increasing reports of positive outcomes, it's high time that corporate policies evolve to address this new reality.

Psychedelic Legislation: Shaping a Future With Mushrooms

As public opinion shifts, so do the laws. The new bill, SB23-290, regulating psychedelic mushrooms, is a testament to this change. It ensures proper implementation of Proposition 122, which was voter-approved, suggesting widespread public support. The legislation effectively restricts personal growth and clarifies the legality of sharing and selling homegrown products, thus making the use of these substances safer and more controlled.

This trend isn't limited to just one state. Maryland has become the 21st state to legalize cannabis for recreational use, while Connecticut residents can now grow up to six cannabis plants. The Psychedelic Medicine Coalition offers further information on these rapidly evolving laws.

While the progress is commendable, the cannabis industry faces many challenges, including the inability to distribute products over state lines and punitive federal tax rates. Still, the tides are turning. Over 60% of Arizonians voted for marijuana legalization, higher than the percentage who voted for Biden in 2020. This public support indicates a strong desire for change.

Former Justice Department Prosecutor on Microdosing at Work

A Happier World, A Brighter Future

The profound potential benefits of psychedelics extend beyond the workplace, hinting at a brighter future for mental health treatments and personal growth. Organizations like Ego Death Trip are exploring these possibilities, promoting research into various psychedelics, from classical ones like LSD to dissociative substances like ketamine.

The potential benefits are vast. From combating addiction to mental health disorders and even sparking creativity, psychedelics are poised to revolutionize our understanding of the human mind and its immense potential.

The promise of new, effective treatments offers hope in a world grappling with rising mental health issues. Psychedelics might be key to transforming our understanding and treatment of various mental health disorders. Whether it's MDMA as a therapeutic aid or the potential of psilocybin in treating depression, there's much to explore.

The conversation surrounding psychedelics is changing. Once viewed solely as dangerous, these mind-altering compounds are now seen as potential tools for wellness, personal growth, and professional success.

To conclude, while we tread cautiously, given their potential for misuse, embracing psychedelics' vast potential is vital. We must work together to create an environment that acknowledges the risks while enabling safe access and research. Through open conversation and a commitment to science, we can navigate the psychedelic renaissance to a future where mental health is prioritized, creativity is enhanced, and the stigma around these substances is a thing of the past.

Resources:

1. Nichols DE. Psychedelics. Pharmacol Rev 2016;68:264–355.doi:10.1124/pr.115.011478

2. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83-102. doi:10.1016/j.pharmthera.2018.11.010

3. Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol. 2016;24 (4):229-268. doi:10.1037/pha0000084

4. Bender D, Hellerstein DJ. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology (Berl). 2022;239(6):1907-1932. doi:10.1007/s00213-021-06049-6

5. Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018;142:72-82. doi:10.1016/j.neuropharm.2018.01.017

6. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254-4276. doi:10.1111/bph.13222

7. Dunlap LE, Andrews AM, Olson DE. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem Neurosci. 2018;9(10):2408-2427. doi:10.1021/acschemneuro.8b00155

8. Wasko MJ, Witt-Enderby PA, Surratt CK. DARK Classics in Chemical Neuroscience: Ibogaine. ACS Chem Neurosci. 2018;9(10):2475-2483. doi:10.1021/acschemneuro.8b00294

9. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011;115(1-2):150-155. doi:10.1016/j.drugalcdep.2010.11.005

10. Vollenweider FX, Smallridge JW. Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry. 2022;55(3):121-138. doi:10.1055/a-1721-2914

11. Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800. doi:10.1371/journal.pone.0030800

12. Oliver CF, Palamar JJ, Salomone A, et al. Synthetic cathinone adulteration of illegal drugs. Psychopharmacology (Berl). 2019;236(3):869-879. doi:10.1007/s00213-018-5066-6

13. Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419-433. doi:10.1080/02791072.2000.10400244

14. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10.1177/02698811221116926

15. Palamar JJ, Salomone A, Barratt MJ. Drug checking to detect fentanyl and new psychoactive substances. Curr Opin Psychiatry. 2020;33(4):301-305. doi:10.1097/YCO.0000000000000607

16. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science [published online ahead of print, 2022 Feb 2]. J Psychopharmacol. 2022;2698811211069100. doi:10.1177/02698811211069100

17. Calvey T, Howells FM. An introduction to psychedelic neuroscience. Prog Brain Res. 2018;242:1-23. doi:10.1016/bs.pbr.2018.09.013

18. Lee HM, Roth BL. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A. 2012;109(6):1820-1821. doi:10.1073/pnas.1121358109

19. Zhang R, Volkow ND. Brain default-mode network dysfunction in addiction. Neuroimage. 2019;200:313-331. doi:10.1016/j.neuroimage.2019.06.036

20. Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419-433. doi:10.1080/02791072.2000.10400244

21. Hernández-Alvarado RB, Madariaga-Mazón A, Ortega A, Martinez-Mayorga K. DARK Classics in Chemical Neuroscience: Salvinorin A [published online ahead of print, 2020 Nov 9]. ACS Chem Neurosci. 2020;10.1021/acschemneuro.0c00608. doi:10.1021/acschemneuro.0c00608

22. Kuypers KP, Ng L, Erritzoe D, et al. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol. 2019;33(9):1039-1057. doi:10.1177/0269881119857204

23. Van Court RC, Wiseman MS, Meyer KW, et al. Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biol. 2022;126(4):308-319. doi:10.1016/j.funbio.2022.01.003

24. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131-181. doi:10.1016/j.pharmthera.2003.11.002

25. Castro Santos H, Gama Marques J. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomed J. 2021;6(1):e128. Published 2021 Feb 11. doi:10.1097/j.pbj.0000000000000128

26. Goldberg SB, Shechet B, Nicholas CR, et al. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020;50(16):2655-2666. doi:10.1017/S003329172000389X

27. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10.1177/02698811221116926

28. Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27-38. doi:10.1111/j.1360-0443.2011.03576.x

29. van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011;59(3):423-429. doi:10.1016/j.yrtph.2011.01.006

30. van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf. 2022;21(1):83-94. doi:10.1080/14740338.2021.1949454

31. Leonard JB, Anderson B, Klein-Schwartz W. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol. 2018;32(12):1286-1294. doi:10.1177/0269881118793086

32. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi:10.1177/0269881108093587

33. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268-1278. doi:10.1177/0269881116662634

34. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166. doi:10.1016/j.neuropharm.2018.05.012

35. Nichols DE, Grob CS. Is LSD toxic?. Forensic Sci Int. 2018;284:141-145. doi:10.1016/j.forsciint.2018.01.006

36. Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004;99(6):686-696. doi:10.1111/j.1360-0443.2004.00744.x

37. Gee P, Schep LJ, Jensen BP, Moore G, Barrington S. Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases - PubMed (nih.gov). Clin Toxicol (Phila). 2016;54(2):141-146. doi:10.3109/15563650.2015.1115056

38. Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila). 2015;53(2):85-92. doi:10.3109/15563650.2015.1004179

39. Köck P, Froelich K, Walter M, Lang U, Dürsteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022;138:108717. doi:10.1016/j.jsat.2021.108717

40. Bertron JL, Seto M, Lindsley CW. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chem Neurosci. 2018;9(10):2459-2474. doi:10.1021/acschemneuro.8b0026

41. Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics [published online ahead of print, 2021 Jul 12]. Psychopharmacology (Berl). 2021;10.1007/s00213-021-05876-x. doi:10.1007/s00213-021-05876-x

42. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-540.

43. Müller F, Kraus E, Holze F, et al. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants [published online ahead of print, 2022 Jan 25]. Psychopharmacology (Berl). 2022;10.1007/s00213-022-06066-z. doi:10.1007/s00213-022-06066-z

44. Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333-360. doi:10.1007/7854_2016_457

45. Martinotti G, Santacroce R, Pettorruso M, et al. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci. 2018;8(3):47. Published 2018 Mar 16. doi:10.3390/brainsci8030047

46. Castellani D, Pirola GM, Gubbiotti M, et al. What urologists need to know about ketamine-induced uropathy: A systematic review. Neurourol Urodyn. 2020;39(4):1049-1062. doi:10.1002/nau.24341

47. Fonseca DA, Ribeiro DM, Tapadas M, Cotrim MD. Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms. Eur J Pharmacol. 2021;903:174156. doi:10.1016/j.ejphar.2021.174156

48. Ona G, Rocha JM, Bouso JC, Hallak JEC, Borràs T, Colomina MT, Dos Santos RG. The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020). Psychopharmacology (Berl). 2021 Aug 18. doi: 10.1007/s00213-021-05964-y. Epub ahead of print. PMID: 34406452.

49. Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73(10):613-627. doi:10.1111/pcn.12902

50. Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Focus (Am Psychiatr Publ). 2021;19(1):95-115. doi:10.1176/appi.focus.19104

51. Fink M, Simeon J, Haque W, Itil T. Prolonged adverse reactions to LSD in psychotic subjects. Arch Gen Psychiatry-. 1966;15(5):450-454. doi:10.1001/archpsyc.1966.01730170002002

52. Zeifman RJ, Singhal N, Breslow L, Weissman CR. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review [published correction appears in ACS Pharmacol Transl Sci. 2022 Feb 22;5(3):176]. ACS Pharmacol Transl Sci. 2021;4(2):436-451. Published 2021 Mar 11. doi:10.1021/acsptsci.1c00024

53. Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in Chemical Neuroscience: Ketamine. ACS Chem Neurosci. 2017;8(6):1122-1134. doi:10.1021/acschemneuro.7b00074

54. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301-1308. doi:10.1176/ajp.148.10.1301

55. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study [published correction appears in Addiction. 2010 Apr;105(4):766]. Addiction. 2010;105(1):121-133. doi:10.1111/j.1360-0443.2009.02761.x

56. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol. 2007 Feb;7(1):48-55. doi: 10.1016/j.coph.2006.08.013. Epub 2006 Nov 9. PMID: 17097347.

57. Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychother Psychosom. 2021;90(1):41-48. doi:10.1159/000510703

58. van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf. 2022;21(1):83-94. doi:10.1080/14740338.2021.1949454

59. Ivory ST, Rotella JA, Schumann J, Greene SL. A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD). Clin Toxicol (Phila). 2022;60(8):966-969. doi:10.1080/15563650.2022.2053150

60. D'Errico S. Commentary. Fentanyl-related death and the underreporting risk. J Forensic Leg Med. 2018;60:35-37. doi:10.1016/j.jflm.2018.09.007

61. Holbrook BD, Rayburn WF. Teratogenic risks from exposure to illicit drugs. Obstet Gynecol Clin North Am. 2014;41(2):229-239. doi:10.1016/j.ogc.2014.02.008

62. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. Congenital anomalies after prenatal ecstasy exposure. Lancet. 1999;354(9188):1441-1442. doi:10.1016/s0140-6736(99)02423-x

63. Singer LT, Moore DG, Min MO, et al. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016;54:22-28. doi:10.1016/j.ntt.2016.01.003

64. Ryu IS, Kim OH, Lee YE, Kim JS, Li ZH, Kim TW, Lim RN, Lee YJ, Cheong JH, Kim HJ, Lee YS, Steffensen SC, Lee BH, Seo JW, Jang EY. The Abuse Potential of Novel Synthetic Phencyclidine Derivative 1-(1-(4-Fluorophenyl)Cyclohexyl) Piperidine (4'-F-PCP) in Rodents. Int J Mol Sci. 2020 Jun 29;21(13):4631. doi: 10.3390/ijms21134631

65. American Psychiatric Association, Substance-Related and Addictive Disorders, Diagnostic and Statistical Manual of Mental Disorders, 10.1176/appi.books.9780890425787, (2022)

66. Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012;123(1-3):132-140. doi:10.1016/j.drugalcdep.2011.10.029

67. Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys . Behav Pharmacol. 2004;15(2):149-157. doi:10.1097/00008877-200403000-00007

68. Kokane SS, Armant RJ, Bolaños-Guzmán CA, Perrotti LI. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res. 2020;384:112548. doi:10.1016/j.bbr.2020.112548

69. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295-314. doi:10.1111/j.1755-5949.2008.00059.x

70. Domínguez-Clavé E, Soler J, Elices M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 2016;126(Pt 1):89-101. doi:10.1016/j.brainresbull.2016.03.002

71. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74-88. doi:10.1016/j.brainresbull.2016.04.016

72. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 2019;12(3):184-194. doi:10.2174/1874467211666181010154139

73. Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL. DARK Classics in Chemical Neuroscience: NBOMes [published online ahead of print, 2019 Nov 12]. ACS Chem Neurosci. 2019;10.1021/acschemneuro.9b00528. doi:10.1021/acschemneuro.9b00528

74. de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study [published online ahead of print, 2022 Feb 1]. Addict Biol. 2022;e13143. doi:10.1111/adb.13143

75. Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug Legislative Reform and Legalization in the US. JAMA Psychiatry. Published online December 07, 2022. doi:10.1001/jamapsychiatry.2022.4101

76. Wasson RG. (13 May 1957). "Seeking the magic mushroom."

77. Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom Published online 2020 Aug 31. doi: 10.3390/plants9091127

78. Kargbo R.B. (2020) Psilocybin Therapeutic Research: The Present and Future Paradigm. ACS Medicinal Chemistry Letters, 11(4): 399-402.

79. Ali A., Gordon L., Grant J., Lowe H., et al. (2021) The Therapeutic Potential of Psilocybin. Molecules, 26(10): 2948.

80. Rootman J.M., Kryskow P., Harvey K., et al. (2021) Adults who microdose psychedelics report health-related motivations and lower levels of anxiety and depression compared to non-microdoses—scientific Reports 11, 22479.

81. Goldberg S.B., Pace B.T., Nicholas C.R., et al. (2020) The experimental effects of Psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research 284, 112749.

82. Ross S., Bossis A., Guss J., et al. (2016) Rapid and sustained symptom reduction following Psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Psychopharmacology, 30(12): 1165-1180.

83. Barnby J.M. & M.A. Mehta (03 July 2018) Psilocybin and Mental Health – Don’t Lose Control—frontiers in Psychiatry.

84. Carhart-Harris R.L., Bostridge M., Rucker J., et al. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Psychiatry, 3(7): 619-627.

85. Carhart-Harris R.L., Giribaldi B., Watts R. (2021) The trial of Psilocybin versus Escitalopram for depression. The New England Journal of Medicine, 384: 1402-1411.

86. Hendricks P.S., Johnson M.W. & R.R. Griffiths (2015) Psilocybin, psychological distress, and suicidality. Psychopharmacology, 29(9): 1041-1043.

87. Krediet E., Bostoen T., Breeksema J. et al. (2020) Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology, 23(6): 385-400.

88. Bird C.I., Modlin N.L. & J.H. Rucker (2021) Psilocybin and MDMA for treating trauma-related psychopathology. International Review of Psychiatry, 33(3): 229-249.

89. Schindler E.A.D., Sewell R.A., Gottschalk C.H., et al. (2021) Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 18, 534-543.